Active Pharmaceutical Ingredients
Itraconazole Immediate Release (IR) Pellets are formulated to provide fast and efficient antifungal action by promoting rapid dissolution and absorption of Itraconazole—a broad-spectrum triazole antifungal agent. Designed to overcome the compound’s poor solubility, these pellets are manufactured using optimized layering and coating techniques to enhance bioavailability and gastrointestinal absorption.
| Component | Function |
|---|---|
| Itraconazole | Active Pharmaceutical Ingredient (API) |
| Sugar Spheres / MCC Pellets | Inert core / Neutral starter spheres |
| Hydroxypropyl Methylcellulose (HPMC) | Binder / Film former for drug layering |
| Polysorbate 80 / Sodium Lauryl Sulfate (SLS) | Wetting agent / Solubilizer to enhance dissolution |
| PEG 6000 / PVP K30 | Solubilizer / Stabilizer for improved dispersion |
| Talc / Colloidal Silicon Dioxide | Anti-adherent / Glidant |
| Purified Water | Solvent (evaporated during processing) |
Salius Pharma offers Itraconazole IR Pellets manufactured in USFDA-approved, WHO-GMP, and ISO-certified facilities in India, ensuring adherence to the highest global quality and regulatory standards. Our pellets are formulated using advanced layering and solubilization technologies to enhance bioavailability and provide consistent immediate release. Available in customizable strengths and pellet sizes.
We ensure prompt and reliable shipping worldwide. Delivery times may vary depending on destination, order volume, and regulatory requirements.
Looking to source Itraconazole IR Pellets or other high-quality pharmaceutical pellet formulations?
Whether you need Active Pharmaceutical Ingredients (APIs), excipients, or regulatory support, our team is ready to provide reliable, compliant, and cost-effective solutions tailored to your market needs.
The contents of this page and any attachments are intended solely for the designated recipient(s) and may contain confidential and/or privileged information protected by law.
Any patented products are excluded from our offerings in regions where such patents are currently in force.
The pelletized immediate-release formulation offers uniform dosing and improved stability, making it easier to incorporate into oral capsules or sachets, which simplifies administration for patients.
Salius Pharma utilizes advanced layering and coating techniques combined with validated HPLC methods to ensure consistent potency, stability, and rapid drug release.
Yes, we provide tailored regulatory support including preparation of documentation compliant with USP, BP, and EP standards to facilitate market approval in diverse global regions.